Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00162266 · ClinicalTrials.gov registry record · Phase 2

Abatacept With Methotrexate- Phase IIB

A Phase 2 study of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
524
Enrollment target
20
Study locations

NCT00162266 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 524 participants, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00162266, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
524 participants
Enrollment target
20
Study locations

Study Summary

This study was conducted to assess the safety and tolerability of Abatacept combined with Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept combined with Methotrexate.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Placebo
  • DRUG Abatacept (BMS-188667)

Study Locations (20)

Florida

  • Local Institution - Largo
  • Local Institution - Titusville
  • Local Institution - West Palm Beach

New York

  • Local Institution - Albany
  • Local Institution - Binghamton
  • Local Institution - The Bronx

Alabama

  • Local Institution - Birmingham
  • Local Institution - Huntsville

Massachusetts

  • Local Institution - Springfield
  • Local Institution - Worcester

New Mexico

  • Local Institution - Albuquerque
  • Local Institution - Los Alamos

California

  • Local Institution - Long Beach

Colorado

  • Local Institution - Highlands Ranch

Georgia

  • Local Institution - Rome

Trial Details

FieldValue
Enrollment Target 524 participants
Start Date 2000-10
Est. Completion 2009-09
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00162266

The ClinicalTrials.gov registry entry for NCT00162266 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 524 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (89% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00162266 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, New York, Alabama.

Frequently Asked Questions

What is clinical trial NCT00162266 about?

NCT00162266 is a clinical study titled "Abatacept With Methotrexate- Phase IIB". This study was conducted to assess the safety and tolerability of Abatacept combined with Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept combined with Methotrexate.

What is the current status of trial NCT00162266?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 524 participants. The study started on 2000-10. Estimated completion is 2009-09.

What conditions does trial NCT00162266 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT00162266?

The interventions under investigation include: Placebo (DRUG), Abatacept (BMS-188667) (DRUG).

Who is sponsoring clinical trial NCT00162266?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00162266 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.